Trial Profile
A Multicenter, Open-label Extension Study to Assess the Long-term Safety and Efficacy of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism [EXTENSION OF 700245269]
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Cinacalcet (Primary)
- Indications Primary hyperparathyroidism
- Focus Adverse reactions
- Sponsors Amgen
- 03 Jun 2014 New trial record